Ask AI
Back Back
ASH 2025: Key Studies in Leukemias

CE / CME

Conference to Clinic Highlights From the 2025 ASH Annual Meeting: Key Studies in Leukemias

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: February 27, 2026

Expiration: August 26, 2026

Courtney D. DiNardo
Courtney D. DiNardo, MD, MSCE
Amir T. Fathi
Amir T. Fathi, MD
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Overall Conclusions

Amir T. Fathi, MD:
In terms of the 5 presentations of studies in AML, there is a common theme, which is the tolerability of a hypomethylating agent plus venetoclax with or without a targeted therapy for older patients with AML. These regimens also have the potential for use in younger, fit patients. As stated earlier, I sense a shift from more intensive, burdensome, and toxic induction therapies to nonintensive and better-tolerated outpatient regimens that both older and younger patients can benefit from. Hopefully, we will be able to move to all-oral nonintensive regimens in the future.

Regarding the 2 studies in CML and the use of asciminib in CML, there is hope that dose escalation may elicit deeper responses without significant toxicity when used in the second line after disease progression on a prior TKI.

Courtney D. Dinardo, MD:
The 5 studies in AML really highlight the utility of using a hypomethylating agent and venetoclax as a backbone of choice when evaluating the efficacy and safety of different targeted or nontargeted therapies with the goal to improve and deepen remissions, which will hopefully lead to more durable responses and longer survival in our patients with AML.

I am excited that the PARADIGM study has highlighted that azacitidine/venetoclax is an effective option for younger, fit patients with AML. Now, we can move the development of triplet combinations out of the very frail setting for patients with preexisting comorbid conditions into a population that is likely to tolerate triplets better. This way, we can really, truly evaluate the efficacy and safety of these regimens. Overall, these times are exciting and promising for patients with AML.

With regard to the 2 studies in CML, asciminib is already known to be an effective agent, and it is already FDA approved for patients with CP-CML. The important point is that there are multiple TKIs that are available for us to use, and these TKIs have different safety and tolerability profiles. Also, these TKIs have different roles in different lines of therapy. Even though we think of CML as a treatable, curable malignancy, there are still a lot of nuances in the field. So, it was intriguing to see the results of the asciminib data presented at ASH 2025. 

Do you plan to make any changes in your clinical practice based on what you learned in today’s program?
BACK | NEXT